
Countdown to SLAS Europe: ORYL Photonics SA
With only one week remaining until Europe’s largest event focused on laboratory automation and drug screening, preparations for SLAS Europe 2025 are well under way. Organised by the Society for Laboratory Automation and Screening (SLAS), the conference will be held in Hamburg from 20–22 May. As part of a dedicated series, European Biotechnology Magazine is highlighting twelve of the most innovative SMEs currently operating in the sector. Among them is Switzerland’s ORYL Photonics SA.
Based in Lausanne, ORYL Photonics SA was spun out of the École Polytechnique Fédérale de Lausanne (EPFL) by co-founders Orly Tarun and Nathan Dupertuis. Their academic research at EPFL concentrated on laser-based light scattering techniques to enable rapid and accurate measurement of solubility and aggregation. At SLAS Europe 2025, the company will officially launch its first instrument, designed to accelerate analysis (with a read time of 1–100 ms per well), increase sensitivity (with a measurement time of 15 minutes per 384 well-plate), increase sensitivity (1 µM for compounds with molecular weight <500 Da), and reduce sample requirements (approximately 2 µL of stock solution per solubility data point).
“Our patented light scattering technology is the first to combine high measurement accuracy with minimal consumption of chemicals and drug compounds. The simplified workflow significantly reduces both time and cost,” explains Dupertuis. “We have developed a versatile automated platform to support decision-making with solubility and aggregation profiling under a range of conditions—including variations in pH, solvents, buffers, excipients and salts that is suitable for both small and large molecules, from highly diluted samples to High Concentration Liquid Formulations (>400 mg/mL). It can typically be used in drug discovery, formulation, and production.”
At present, ORYL Photonics offers a fee-for-measurement service using its proprietary instrument. “However, our core business model is centred on instrument sales,” Dupertuis told European Biotechnology. “We will be officially launching our instrument on the market during SLAS Europe 2025 in Hamburg.” The company has also been named a finalist for the SLAS Ignite Award, which recognises the automation start-up with the strongest commercial strategy. “We will be presenting on stage at SLAS, which provides an ideal platform for our announcement,” the co-founder stated. In Hamburg, the company will exhibit in the AveNew exhibition zone, supported by the Society for Laboratory Automation and Screening (SLAS).
European Biotechnology Magazine, as the SLAS’ official EU media partner, will report on the highlights of the SLAS Europe in its June issue. If you like to advertise or contribute with a text, please send an e-mail to Andreas or Oliver, who can give you all information you need to be featured in our print issue or online.